Clinical trials: Inflammation Eye
Cataract
Clinical Study of the Efficacy of the Ophthalmic Emulsion PRO-145 for Inflammation and Pain After Phacoemulsification
objective: To evaluate the efficacy of the ophthalmic emulsion PRO-145 in the treatment of inflammation and pain after phacoemulsification.
- Trial name
- PRO-145/III (NCT03693989)
- Testing
- Difluprednate 0.05%, Prednefrin
- Where
- 5 sites in Mexico
- Volunteers
- 178 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Behcet Disease
1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement
Primary objective of the study was to evaluate the safety and efficacy of canakinumab on the clinical and inflammatory findings of Behced Disease patients with neurologic and vascular involvement.
- Trial name
- Behcet (NCT02756650)
- Testing
- Canakinumab
- Where
- Turkey (Türkiye)
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Ocular Inflammation Associated With Blepharaconjunctivitis
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection…
- Trial name
- NCT00576251
- Testing
- Tobramycin 0.3%/Dexamethasone 0.05%, TOBRADEX
- Where
- United States
- Volunteers
- 221 people
- Sponsor
- Alcon Research
Ocular Inflammation
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
Evaluation of the clinical safety and efficacy of loteprednol etabonate in an ophthalmic base, when compared to vehicle for the treatment of inflammation following cataract surgery.
- Trial name
- NCT00699153
- Testing
- Loteprednol Etabonate, Vehicle of Ophthalmic Loteprednol Etabonate
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bausch & Lomb Incorporated
Cataract
Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery
To demonstrate that the combination formulation of Moxifloxacin/Dexamethasone Eye Drop is effective and safe for the prevention of postoperative inflammation as a consequence of cataract extraction surgery.
- Trial name
- NCT00870103
- Testing
- Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- Alcon Research
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
OTX-14-003: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Ocular Inflammation and Pain After Cataract Surgery
The objective of the study was to evaluate the safety and efficacy of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of post-surgical inflammation and…
- Trial name
- NCT02089113
- Testing
- Dexamethasone
- Volunteers
- 241 people
- Sponsor
- Ocular Therapeutix, Inc.
Inflammation Corneal, Pain, Postoperative
OCS-01 in Treating Inflammation and Pain in Post-cataract Patients
The DX-216 trial is a randomized, double-masked, placebo (vehicle)-controlled study evaluating the efficacy and safety of two doses of OCS-01 compared to vehicle in the treatment of inflammation and pain following cataract…
- Trial name
- SKYGGN (NCT04130802)
- Testing
- OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL
- Where
- 4 sites in United States
- Volunteers
- 153 people
- Sponsor
- Oculis
Ocular Inflammation and Pain
Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery
To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone) depot when placed in the canaliculus of the eyelid for the treatment of ocular inflammation and pain in subjects who have undergone…
- Trial name
- NCT01666210
- Testing
- OTX-DP (Dexamethasone punctum plug)
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Ocular Therapeutix, Inc.
Post Surgical Ocular Inflammation
A Study of TRS01 in Participants With Post-surgical Ocular Inflammation
The objective of this study is to evaluate the safety and preliminary efficacy of TRS01 eye drops as compared to placebo on participants with ocular inflammation after cataract surgery.
- Trial name
- NCT04222725
- Testing
- TRS01 eye drops
- Where
- 5 sites in United States
- Volunteers
- 37 people
- Sponsor
- Tarsier Pharma
Ocular Inflammation and Pain After Cataract Surgery
Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study
This Phase 3 study will evaluate APP13007 in comparison to the matching vehicle placebo in a randomized, parallel-group, double-masked fashion.
- Trial name
- NCT04810962
- Testing
- APP13007, 0.05%
- Where
- 31 sites in United States
- Volunteers
- 370 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Cataract, Inflammation
Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
The objective of this clinical study is to compare the safety and efficacy of mapracorat ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Conditions
- Cataract, Inflammation, Surgery
- Trial name
- NCT01591161
- Testing
- Mapracorat
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Bausch & Lomb Incorporated
Pain, Inflammation
Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract
This is a Phase 2, multi-center, randomized, parallel-arm, double-masked, placebo-controlled study. One (1) to 2 days prior to their scheduled cataract surgery, each study subject will be randomized (2:1) in to one of two…
- Trial name
- NCT03496467
- Testing
- Nepafenac PPDS
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Mati Therapeutics Inc.
Inflammation and Pain Following Ocular Surgery
RTA 408 Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain Following Ocular Surgery
This study assesses the efficacy and safety of two concentrations of RTA 408 Ophthalmic Suspension in the treatment of patients who have inflammation and pain following ocular surgery.
- Trial name
- NCT02065375
- Testing
- Omaveloxolone Ophthalmic Suspension 1.0%, Omaveloxolone Opthalmic Suspension 0.5%
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- Biogen
Cataract
Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery
The objective of this clinical study is to compare the safety and efficacy of Mapracorat Ophthalmic Suspension, 3% to vehicle for the treatment of postoperative inflammation and pain following cataract surgery.
- Trial name
- NCT01230125
- Testing
- Mapracorat, Vehicle
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation and Pain After Cataract Surgery
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of APP13007 to Treat Inflammation and Pain After Cataract Surgery
This is a Phase 2a, 2-part study (designated Parts A and B) that will evaluate APP13007 dose strength and dosing frequency in a randomized double-masked fashion for comparison to the respective matching vehicle placebo.
- Trial name
- NCT04089735
- Testing
- APP13007, 0.05%, APP13007, 0.1%
- Where
- 9 sites in United States
- Volunteers
- 165 people
- Sponsor
- Formosa Pharmaceuticals, Inc.
Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis
Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,
This was a multi-center, randomized, active-controlled, open-label study. Approximately 24 patients with active, non-infectious intermediate-, posterior-, or panuveitis requiring systemic immunosuppressive therapy were enrolled.
- Conditions
- Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
- Trial name
- NCT01526889
- Testing
- LFG316, Conventional Therapy
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Cataract, Inflammation
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
- Trial name
- NCT00905450
- Testing
- BOL-303242-X, Vehicle for BOL-303242-X
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Bausch & Lomb Incorporated
Pain, Inflammation
Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery
Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery
- Trial name
- NCT00853970
- Testing
- Bromfenac Ophthalmic Solution
- Where
- United States
- Volunteers
- 299 people
- Sponsor
- Bausch & Lomb Incorporated
Ocular Inflammation
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
To evaluate the clinical safety and efficacy of Loteprednol Etabonate Ophthalmic Ointment, 0.5% vs. vehicle for the treatment of inflammation following cataract surgery
- Trial name
- NCT00645671
- Testing
- 0.5% Loteprednol Etabonate Ophthalmic Ointment, Vehicle of Loteprednol Etabonate Ophthalmic Ointment
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- Bausch & Lomb Incorporated
Sjogren's Syndrome
Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention
The primary purpose of this study is to quantify the change in expression of biomarkers on the ocular surface of Sjogren's Syndrome participants after treatment with Maxidex.
- Trial name
- NCT00631358
- Testing
- Maxidex, No treatment
- Where
- 2 sites in Canada
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Alcon Research